scholarly journals Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial

2021 ◽  
Author(s):  
Sean Wharton ◽  
Peter Yin ◽  
Melonie Burrows ◽  
Errol Gould ◽  
Jessica Blavignac ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Extended Release ◽  
Cardiovascular Outcome ◽  
Absolute Difference ◽  
Mean Absolute Difference ◽  
Post Hoc Analysis ◽  
Cardiovascular Outcome Trial ◽  
Post Hoc

Abstract Background Extended-release naltrexone/bupropion (NB) is indicated for chronic weight management. Incretin agents are recommended for patients with type 2 diabetes. This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents. Methods This was a post-hoc analysis of NB vs. placebo (PL) among subjects with type 2 diabetes stable on an incretin agent prior to randomization in a double-blind, PL-controlled cardiovascular outcome trial (N = 1317). Results Over 1 year, mean weight loss was significantly greater among NB patients vs. PL among those taking DPP-4i (mean absolute difference 4.6% [p < 0.0001]) and those taking GLP-1RAs (mean absolute difference 5.2%, p < 0.0001). Proportions of subjects achieving 5% weight loss were significantly greater for NB vs. PL at weeks 26 and 52 among those taking DPP-4is or GLP-1RAs. There were no significant differences in effectiveness observed between NB + DPP-4i and NB + GLP-1RA or between PL + DPP-4i and PL + GLP-1RA in any of the analyses. Serious adverse events were reported by 9.1% and 11.1% for PL + DPP-4i and PL + GLP-1RA, respectively, and 13.3% and 12.4% of NB + DPP-4i and NB + GLP-1RA, respectively. Conclusion NB appears to be effective in reducing weight in patients with T2DM and obesity/overweight who are taking DPP-4ihibitors or GLP-1RA. The SAE rates in all arms of this analysis were lower than have been reported in other cardiovascular outcome trials in type 2 diabetes.

651-P: Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 651-P
Author(s):  
ENZO BONORA ◽  
JUAN P. FRIAS ◽  
RALEIGH MALIK ◽  
ANITA KWAN ◽  
SOHINI RAHA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Post Hoc Analysis ◽  
Induce Weight Loss ◽  
Post Hoc ◽  
Baseline Bmi ◽  
Higher Doses

Increased sclerostin and bone turnover after diet-induced weight loss in type 2 diabetes: a post hoc analysis of the MADIAB trial

Endocrine ◽  
2016 ◽  
Vol 56 (3) ◽  
pp. 667-674 ◽  
Author(s):  
Rocky Strollo ◽  
Andreea Soare ◽  
Yeganeh Manon Khazrai ◽  
Antonio Di Mauro ◽  
Andrea Palermo ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Bone Turnover ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide

2019 ◽  
Vol 104 (9) ◽  
pp. 4078-4086 ◽  
Author(s):  
Vivian A Fonseca ◽  
Matthew S Capehorn ◽  
Satish K Garg ◽  
Esteban Jódar Gimeno ◽  
Oluf H Hansen ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Weight Loss ◽  
Extended Release ◽  
Outcome Measure ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Post Hoc ◽  
The Relationship

AbstractContextSemaglutide, a once-weekly glucagon-like peptide-1 analog approved for use in patients with type 2 diabetes (T2D), demonstrated superior body weight (BW) reductions and decreased insulin resistance (IR) vs comparators across the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) 1–3 clinical trials.ObjectiveTo investigate the relationship between IR and BW across the SUSTAIN 1–3 trials.DesignPost hoc analysis of the SUSTAIN 1–3 trials.SettingThree hundred and eleven sites in 30 countries.Patients or other participants2432 subjects with T2D.InterventionsSemaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg).Main Outcome MeasureTo assess the extent of the effect on IR that is mediated (indirect effect) and not mediated (direct effect) by the effect on BW.ResultsAcross SUSTAIN 1–3, mean BW was significantly reduced with semaglutide 0.5 mg (3.7 kg to 4.3 kg; P < 0.0001) and semaglutide 1.0 mg (4.5 kg to 6.1 kg; P < 0.0001) vs comparators (1.0 kg to 1.9 kg). There were greater reductions in IR with semaglutide 0.5 mg (27% to 36%) and semaglutide 1.0 mg (32% to 46%) vs comparators (17% to 28%). Greater reductions in BW were generally associated with greater decreases in IR. The effect on IR was primarily mediated by weight loss (70% to 80% and 34% to 94%, for semaglutide 0.5 mg and 1.0 mg, respectively, vs comparator).ConclusionsSemaglutide consistently reduced BW and IR in subjects with T2D in SUSTAIN 1–3. In this analysis, IR improvement was positively associated with, and primarily mediated by, the effect of semaglutide on BW.

Abstract #295 GLP-1 Receptor Agonists and Death From Any Cause in Elderly Patients with Type 2 Diabetes Mellitus: A Post-Hoc Analysis

2018 ◽  
Vol 24 ◽  
pp. 80-81
Author(s):  
Konstantinos Toulis ◽  
Krishna Gokhale ◽  
G. Neil Thomas ◽  
Wasim Hanif ◽  
Krishnarajah Nirantharakumar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly Patients ◽  
Post Hoc Analysis ◽  
Receptor Agonists ◽  
Post Hoc

Abstract #245 Efficacy and Safety of Semaglutide in Elderly Subjects with Type 2 Diabetes: A Post Hoc Analysis of the Sustain 7 Trial

2018 ◽  
Vol 24 ◽  
pp. 51-52
Author(s):  
Vanita Aroda ◽  
Danny Sugimoto ◽  
David Trachtenbarg ◽  
Mark Warren ◽  
Gurudutt Nayak ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Elderly Subjects ◽  
Efficacy And Safety ◽  
Post Hoc Analysis ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document